INOTIV INC
Inotiv provides contract research services to the pharmaceutical, biotechnology, and medical device industries.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INOTIV's stock with a target price of $6.67, indicating strong potential growth.
Financial Health
Inotiv Inc shows moderate revenue and cash flow, but profitability could be improved.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NOTV
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Outsourcing trend tailwind
Pharma and biotech increasingly outsource preclinical testing, which can support demand for INOTIV’s services, though revenue can be uneven by quarter.
Industry positioning matters
A focused CRO can win niche work and partnerships, but competition from larger global players and consolidation are ongoing challenges.
Small-cap considerations
Smaller market cap means potential for higher returns but also greater volatility and liquidity risk; review financials and risk disclosures carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
